EQT agrees to take over Qiagen in $10.8 billion private equity deal
Sweden's EQT agreed to take over diagnostics firm Qiagen for about €9.6 billion ($10.78 billion), a premium of 8.6% to the last close, Reuters reported.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
On Wednesday, Qiagen announced that it has accepted an offer from Swedish private equity house EQT, which would pay roughly €9.6 billion ($10.78 billion) for the company, according to Reuters. The exchange rate used in the report was $1 = 0.8904 euros.
EQT would pay €46.50 ($52.22) per share, 8.6% above Qiagen's last closing price. The agreement puts an end to years of speculation about a takeover of the European diagnostics group. Reuters noted that private equity appetite for the sector is rising, as demand for molecular tests grows and makes such firms attractive targets.
why it matters
For investors, the deal removes years of takeover speculation around Qiagen and signals that private equity funds are looking more actively at medical diagnostics. The 8.6% premium to the last closing price is the key figure for shareholders weighing the offer against the current share price.
market impact
Qiagen and diagnostics stocks: private equity interest supports sector valuations, while the offer anchors Qiagen's share price
tags
instruments
sources
- Buyout firm EQT to acquire Qiagen for $10.8 billion — Reuters, 21 October 2026 at 21:44 UTC
- Buyout firm EQT to acquire Qiagen for $10.8 billion — Reuters, 21 October 2026 at 21:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗